Development and characterization of nanobubbles containing paclitaxel and survivin inhibitor YM155 against lung cancer


BAŞPINAR Y. , Erel-Akbaba G., KOTMAKÇI M. , AKBABA H.

INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.566, pp.149-156, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 566
  • Publication Date: 2019
  • Doi Number: 10.1016/j.ijpharm.2019.05.039
  • Title of Journal : INTERNATIONAL JOURNAL OF PHARMACEUTICS
  • Page Numbers: pp.149-156

Abstract

Lung cancer remains 23% of cancer-related death worldwide, ranking on first place for men and second place for women. Almost each cancer type has a great deal in common, overexpression of the apoptosis inhibitor survivin. Chemotherapy with anticancer drugs is leading to side effects. Drug targeting by the use of nanobubbles is a useful strategy to reduce side effects. Nanobubbles in cancer are one of the most investigated carriers in the last years. The size of nanobubbles (1-500 nm) is bigger than the pore size of healthy tissues, but smaller than the pores of cancer tissues. Thus, it is not possible for the drug to leave the blood stream and enter the tissue, but it can enter the cancer tissue through the pores, where it can accumulate. Therefore, the probability of undesired side effects decreases. For that reason, the development of nanobubbles containing paclitaxel and survivin inhibitor sepantronium bromide (YM155) were carried out. Characterization studies in terms of particle size, size distribution, zeta potential and morphology, and investigation of their effects on lung cancer cells were performed. To the best of our knowledge, there is no information in the literature about combining paclitaxel and YM155 loaded nanobubbles with ultrasound exposure.